AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14704548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (timolol arm)
Number of subjects: 120
Study 14704548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.01% (latanoprost group)
Number of subjects: 120
Study 11534537 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 4
Study 11534537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 9273030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transconjunctival injection
Number of subjects: 46
Study 9273030 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous injection
Number of subjects: 46
Study 8484970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus danazol
Number of subjects: 183
Study 8484970 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus placebo
Number of subjects: 183
Study 3119785 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 or 24 Gy of radiation therapy (RT) to craniospinal plus abdominal RT including the ovaries
Number of subjects: 97
Study 3119785 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 or 24 Gy of radiation therapy (RT) to craniospinal RT
Number of subjects: 97
Study 3119785 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 or 24 Gy of radiation therapy (RT) to cranial RT
Number of subjects: 97
Study 3119785 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal plus abdominal RT
Number of subjects: 97
Study 3119785 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal RT
Number of subjects: 97
Study 30768490 — intervention group
Group type: EXPERIMENTAL
Intervention: High entry sCD163
Number of subjects: 67
Study 30768490 — intervention group
Group type: EXPERIMENTAL
Intervention: High 6-month post-ART sCD163
Number of subjects: 67
Study 28774856 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 0
Study 28774856 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 0
Study 28774856 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 3.2 mg/kg (in mice)
Number of subjects: 0
Study 28774856 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 10 mg/kg (in mice)
Number of subjects: 0
Study 28774856 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 32 mg/kg (in mice)
Number of subjects: 0
Study 26201229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing adhesive (One-up Bond F Plus - OP)
Number of subjects: 17
Study 26201229 — intervention group
Group type: EXPERIMENTAL
Intervention: MDPB and fluoride-containing adhesive (Clearfil Protect Bond - PB)
Number of subjects: 17
Study 26201229 — intervention group
Group type: COMPARATOR
Intervention: Control group (enamel and dentin blocks without adhesive)
Number of subjects: 17
Study 23608567 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively aspheric IOL (Acri.Smart 36A)
Number of subjects: 2
Study 23608567 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherically neutral IOL (Akreos MI‐60)
Number of subjects: 2
Study 23608567 — intervention group
Group type: COMPARATOR
Intervention: Conventional spherical hydrophobic IOL (Acrysof SN60AT)
Number of subjects: 2
Study 22189151 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyalkylamide gel (PAIG) treatment
Number of subjects: 36
Study 22189151 — intervention group
Group type: COMPARATOR
Intervention: Delayed PAIG injections (12 weeks later)
Number of subjects: 36
Study 19327074 — intervention group
Group type: EXPERIMENTAL
Intervention: Family/Adolescent-Centered (FACE) Advance Care Planning intervention
Number of subjects: 38
Study 19327074 — intervention group
Group type: COMPARATOR
Intervention: Control group (Developmental History, Health Tips, Future Plans)
Number of subjects: 38
Study 16702866 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTI‐FREE Express
Number of subjects: 8
Study 16702866 — intervention group
Group type: COMPARATOR
Intervention: ReNu MultiPlus
Number of subjects: 8
Study 15740172 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care intervention
Number of subjects: 0
Study 11740191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 34
Study 11740191 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 34
Study 11740191 — intervention group
Group type: COMPARATOR
Intervention: Indinavir
Number of subjects: 34
Study 9758086 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS monotherapy
Number of subjects: 0
Study 9758086 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) monotherapy
Number of subjects: 0
Study 9758086 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS alone or in combination with HCTZ
Number of subjects: 0
Study 8110558 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 20 micrograms kg‐1 at profound block (5-10% recovery)
Number of subjects: 57
Study 8110558 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms kg‐1 at profound block (5-10% recovery)
Number of subjects: 57
Study 8110558 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 20, 40, or 80 micrograms kg‐1 at light block (40-50% recovery)
Number of subjects: 57
Study 8110558 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 20 micrograms kg‐1 at light block (40-50% recovery)
Number of subjects: 57
Study 3377211 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of fentanyl 10 micrograms/ml with bupivacaine 0.1%
Number of subjects: 107
Study 3377211 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion of morphine 0.1 mg/ml with bupivacaine 0.1%
Number of subjects: 107
Study 29603591 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 430 mg/m2/day (days 1-4; 8-11) in combination with isotretinoin 80 mg/m2/dose (days 1-14)
Number of subjects: 29
Study 29603591 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 430 mg/m2/day (days 1-4; 8-11)
Number of subjects: 29
Study 26503614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) for cows' milk allergy
Number of subjects: 28
Study 25593233 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 20 mg BID
Number of subjects: 504
Study 25593233 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg BID
Number of subjects: 504
Study 25593233 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 504
Study 23878381 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoes on
Number of subjects: 33
Study 23878381 — intervention group
Group type: COMPARATOR
Intervention: Shoes off
Number of subjects: 33
Study 23878381 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual condition (eyes open)
Number of subjects: 33
Study 23878381 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual condition (eyes closed)
Number of subjects: 33
Study 20944074 — intervention group
Group type: EXPERIMENTAL
Intervention: EZG (RTG) 600 mg/d
Number of subjects: 538
Study 20944074 — intervention group
Group type: EXPERIMENTAL
Intervention: EZG (RTG) 900 mg/d
Number of subjects: 538
Study 20944074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 18187486 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (BCT)
Number of subjects: 9388
Study 18187486 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy (MT)
Number of subjects: 9388
Study 16298249 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (2mg per day)
Number of subjects: 115
Study 16298249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 12823389 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (80 mg, intravenous, with possible repeat dose)
Number of subjects: 102
Study 12823389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 9685441 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and attitude program and adaptation of physical education (8-week intervention)
Number of subjects: 422
Study 9685441 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based intervention (8-week intervention)
Number of subjects: 422
Study 9685441 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual teaching and physical education)
Number of subjects: 422
Study 9685441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 422
Study 7851466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tropisetron plus ketanserin
Number of subjects: 5
Study 7851466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 5
Study 7851466 — intervention group
Group type: COMPARATOR
Intervention: Cholera toxin alone
Number of subjects: 5
Study 7851466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron alone
Number of subjects: 5
Study 2647123 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg to 60 mg daily)
Number of subjects: 0
Study 1106185 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 60
Study 1106185 — intervention group
Group type: COMPARATOR
Intervention: UGI barium series
Number of subjects: 60
Study 1106185 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy and UGI series
Number of subjects: 60
Study 31023005 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI + Se
Number of subjects: 103
Study 31023005 — intervention group
Group type: COMPARATOR
Intervention: MMI
Number of subjects: 103
Study 28789468 — intervention group
Group type: EXPERIMENTAL
Intervention: mNMES
Number of subjects: 0
Study 28789468 — intervention group
Group type: EXPERIMENTAL
Intervention: nNMES
Number of subjects: 0
Study 28789468 — intervention group
Group type: EXPERIMENTAL
Intervention: iNMES
Number of subjects: 0
Study 23351836 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based aftercare with weekly writing tasks and therapeutic feedback, a patient forum, a self-test and relaxation exercises (n = 400)
Number of subjects: 800
Study 23351836 — intervention group
Group type: COMPARATOR
Intervention: Regular e-mail reminders with links to publicly accessible information about stress management and coping (Control group, n = 400)
Number of subjects: 800
Study 21288539 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐AT (computer-assisted treatment program, My Sentence Builder)
Number of subjects: 34
Study 21288539 — intervention group
Group type: EXPERIMENTAL
Intervention: nC‐AT (non computer-assisted treatment, conventional language stimulation procedures)
Number of subjects: 34
Study 21288539 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 34
Study 19853105 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal matrix sealant
Number of subjects: 415
Study 19853105 — intervention group
Group type: COMPARATOR
Intervention: Alternative topical hemostatic agents
Number of subjects: 415
Study 17368254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (2 ampules of oxytocin at 10 u/mL/amp added to 1000 mL saline at 40 mU/min)
Number of subjects: 60
Study 17368254 — intervention group
Group type: COMPARATOR
Intervention: Control group (without oxytocin infusion)
Number of subjects: 60
Study 15222727 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of ciprofloxacin 750 mg (supplied by Dr. August Wolff GmbH and Co., Germany)
Number of subjects: 24
Study 11494803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed guidelines and seminars to school teachers
Number of subjects: 0
Study 10026839 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 1 mg
Number of subjects: 50
Study 10026839 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 10 mg
Number of subjects: 50
Study 10026839 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 100 mg
Number of subjects: 50
Study 10026839 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 300 mg
Number of subjects: 50
Study 10026839 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 600 mg
Number of subjects: 50
Study 10026839 — intervention group
Group type: COMPARATOR
Intervention: AVP (control)
Number of subjects: 50
Study 7987490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral haloperidol
Number of subjects: 0
Study 7987490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol decanoate
Number of subjects: 0
Study 2106534 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol in combination with carbamazepine
Number of subjects: 0
Study 2106534 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol in combination with lithium carbonate
Number of subjects: 0
Study 2106534 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol with added carbamazepine
Number of subjects: 0
Study 785949 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 100
Study 785949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: CRADLE intervention (novel vital sign device and training package)
Number of subjects: 536233
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclampsia cases
Number of subjects: 536233
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate availability
Number of subjects: 536233
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: Stillbirth or neonatal death
Number of subjects: 536233
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: Age distribution of eclampsia cases
Number of subjects: 536233
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: Place of first eclamptic fit
Number of subjects: 536233
Study 29077152 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight Sodium Hyaluronate (3%) plus saline solution (NaCl 0.9%) twice a day for 30 days
Number of subjects: 48
Study 29077152 — intervention group
Group type: COMPARATOR
Intervention: Saline solution twice a day for 30 days
Number of subjects: 48
Study 25451987 — intervention group
Group type: EXPERIMENTAL
Intervention: Office visit with a primary care physician within 7 days after discharge
Number of subjects: 3661
Study 25451987 — intervention group
Group type: EXPERIMENTAL
Intervention: Office visit with any physician within 7 days after discharge
Number of subjects: 3661
Study 25451987 — intervention group
Group type: COMPARATOR
Intervention: No office visit within 7 days after discharge
Number of subjects: 3661
Study 23981905 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message follow-up
Number of subjects: 710
Study 23981905 — intervention group
Group type: COMPARATOR
Intervention: Online follow-up
Number of subjects: 710
Study 23981905 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message follow-up (Black men)
Number of subjects: 710
Study 23981905 — intervention group
Group type: COMPARATOR
Intervention: Online follow-up (Black men)
Number of subjects: 710
Study 23981905 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message follow-up (Hispanic men)
Number of subjects: 710
Study 23981905 — intervention group
Group type: COMPARATOR
Intervention: Online follow-up (Hispanic men)
Number of subjects: 710
Study 23981905 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message follow-up (White men)
Number of subjects: 710
Study 23981905 — intervention group
Group type: COMPARATOR
Intervention: Online follow-up (White men)
Number of subjects: 710
Study 21613972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Exeter V40 stem with torsional loading (group I)
Number of subjects: 20
Study 21613972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Exeter V40 stem with anterior loading (group II)
Number of subjects: 20
Study 21613972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Exeter V40 stem with lateral loading (group III)
Number of subjects: 20
Study 21613972 — intervention group
Group type: COMPARATOR
Intervention: Uninstrumented femurs tested in a four-point bending assay (group IV and V)
Number of subjects: 20
Study 19372111 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip repair with an Abbé flap
Number of subjects: 2
Study 19372111 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 2
Study 16944822 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulo device intervention (active and passive range of motion of the ankle, performed three times a week for 30 min over six weeks)
Number of subjects: 18
Study 16326693 — intervention group
Group type: COMPARATOR
Intervention: 2-week antimicrobial protocol
Number of subjects: 80
Study 16326693 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week antimicrobial protocol
Number of subjects: 80
Study 13678770 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 2.5-10 mg per day for 2 years
Number of subjects: 203
Study 13678770 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate for 4 years
Number of subjects: 203
Study 13678770 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate for 6 years
Number of subjects: 203
Study 13678770 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg per day for 2 years
Number of subjects: 203
Study 13678770 — intervention group
Group type: COMPARATOR
Intervention: Alendronate withdrawal
Number of subjects: 203
Study 13678770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone markers
Number of subjects: 203
Study 10515039 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisate (300 mg, 1 tablet twice a day for 4-6 weeks)
Number of subjects: 30
Study 10515039 — intervention group
Group type: COMPARATOR
Intervention: Conventional antirheumatic therapy
Number of subjects: 30
Study 7556959 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IGF‐I (rhIGF‐I) (10 micrograms.kg‐1.h‐1 s.c.)
Number of subjects: 8
Study 7556959 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 8
Study 1702977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (RL group, n = 6)
Number of subjects: 18
Study 1702977 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch (HES group, n = 6)
Number of subjects: 18
Study 1702977 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin (HA group, n = 6)
Number of subjects: 18
Study 438427 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (N = 32) with individually designed prescriptive techniques implemented by trained college student aides.
Number of subjects: 64
Study 438427 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (N = 32).
Number of subjects: 64
Study 30942034 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and tuina combined with phacoemulsification
Number of subjects: 68
Study 30942034 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 68
Study 29112963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention strategy (CIS)
Number of subjects: 2197
Study 29112963 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 2197
Study 29112963 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS
Number of subjects: 2197
Study 29112963 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 2197
Study 25835622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate Dose (ID) - 76.8Gy < BED 10 < 100.8 Gy (e.g., >64 Gy/32 fr and <74 Gy/37 fr)
Number of subjects: 1274
Study 25835622 — intervention group
Group type: COMPARATOR
Intervention: Standard Dose (SD) - 72Gy ≤ BED 10 ≤ 76.8 Gy (e.g., 60‐64 Gy/30‐32 fractions)
Number of subjects: 1274
Study 25835622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate Dose (ID)
Number of subjects: 1274
Study 24270132 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 31
Study 24270132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21458622 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 1187
Study 21458622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1187
Study 19536605 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued pharmacological treatment
Number of subjects: 319
Study 19536605 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive treatment
Number of subjects: 319
Study 19536605 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe myocardial ischemia
Number of subjects: 319
Study 19536605 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 319
Study 16776781 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeglasses and magnifiers (immediate intervention group)
Number of subjects: 131
Study 16776781 — intervention group
Group type: COMPARATOR
Intervention: Control group (prescription and voucher after 3 months)
Number of subjects: 131
Study 14757691 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent deployment in diabetic patients
Number of subjects: 418
Study 14757691 — intervention group
Group type: COMPARATOR
Intervention: Stent deployment in nondiabetic patients
Number of subjects: 418
Study 14757691 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller vessel reference diameter (RD)
Number of subjects: 418
Study 14757691 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater stented length of vessel
Number of subjects: 418
Study 14757691 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced body mass index (BMI)
Number of subjects: 418
Study 11579891 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) - dosage: pyrimethamine 1.25 mg/kg and sulfadoxine 25 mg/kg, single dose
Number of subjects: 220
Study 11579891 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil (PG) plus Dapsone (DS) - dosage: PG 10 mg/kg and DS 2.5 mg/kg each day for 3 days
Number of subjects: 220
Study 11579891 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil (PG) plus Dapsone (DS)
Number of subjects: 220
Study 9443139 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy in addition to coaching in breathing from partners during labor
Number of subjects: 28
Study 9443139 — intervention group
Group type: COMPARATOR
Intervention: Coaching in breathing alone
Number of subjects: 28
Study 8098885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nootropic piracetam (daily dosage 1.2 g)
Number of subjects: 0
Study 8098885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3755554 — intervention group
Group type: EXPERIMENTAL
Intervention: Brufen 200 mg tablets
Number of subjects: 18